Strategic augmentation of digital cognitive tests with new blood biomarkers

Important results from the project

** Denna text är maskinöversatt ** Cognitive disorders are among the most costly diagnoses for society. The purpose aims at preventive interventions in early cognitive failure that can provide increased quality of life and delay serious illness. The diagnosis of the future will require both cognitive testing, collection of anamnesis from the patient and relatives, in combination with new blood-based biomarkers. By integrating cognitive tests with blood biomarkers, we want to be able to offer a product that has a good chance of contributing to accurate cognitive diagnoses.

Expected long term effects

** Denna text är maskinöversatt ** Today, cognitive manual tests are used in combination with spinal fluid and imaging of the brain. The development shows that there will soon be new blood biomarkers for Alzheimer´s, here there are big socio-economic gains if you combine digital cognitive testing with blood biomarkers. The payers are primary care centers and the specialist clinics that carry out cognitive investigations. A health economic analysis indicates a cost saving for care of about 25%, driven by time savings and a proven ability to diagnose earlier in the patient flow.

Approach and implementation

** Denna text är maskinöversatt ** By integrating new elements in Geras Solutions´s cognitive tests, we can offer a product that has improved sensitivity and specificity and is also compatible to be rolled out together with new blood biomarkers. Identification of analog test moments which can be incorporated into the digital test to create better user-friendliness. Validation of the blood biomarker results against the digital test and checking for consistency. Development of processes for blood-biomarker sampling in the clinical setting of blood-based biomarkers.